Preventing RSV bronchiolitis in vulnerable infants: The role of palivizumab

Paediatric Respiratory Reviews

Volumn 10, Issue 3, 2009, Pages 143-147

  Fitzgerald, Dominic A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

bronchiolitis; Chronic neonatal lung disease; Haemodynamically significant congenital heart disease; Infants; Palivizumab; Respiratory syncytial virus RSV

Indexed keywords

PALIVIZUMAB; PLACEBO;

ARTIFICIAL VENTILATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; DRUG USE; ECONOMIC ASPECT; HUMAN; INFECTION RISK; INTENSIVE CARE; NEWBORN DISEASE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK REDUCTION; VIRAL BRONCHIOLITIS; VULNERABLE POPULATION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHIOLITIS; HOSPITALIZATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 67949109459     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2009.06.002     Document Type: Review

References (45)

1. Glezen W.P., Taber L.H., Frank A.L., et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140 (1986) 543-546
2. De Boeck K. Respiratory syncytial virus bronchiolitis: clinical aspects and epidemiology. Monaldi Arch Chest Dis 51 (1996) 210-213
3. Murphy B., Phelan P.D., Jack I., et al. Seasonal pattern in childhood viral lower respiratory tract infections. Med J Aust. 1 (1980) 22-24
4. Fitzgerald D.A., Kilham H.A., and Bronchiolitis:. Assessment and evidence based management. Med J Aust. 180 (2004) 399-404
5. Romero J.R. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J. 22 (2003) S46-54
6. Lanari M., Giovannini M., Giuffre L., et al. Investigators RADAR Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol. 33 (2002) 458-465
7. Institute of Medicine [1998]. Institute of Medicine Committee on Issues and Priorities for new vaccine development; prospects fro immunizing against respiratory syncytial virus, In: New vaccine Development, Establishing Priorities, Washington DC: National Academy of Science Press; 1998: 1: 397-409.
8. Boyce T.G., Mellen B.G., Mitchel Jr. E.F., et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 137 (2000) 865-870
9. Cunningham C.K., Macmillan J.A., and Gross S.J. Rehospitalisation for respiratory illness in infants of less than 32 weeks gestation. Pediatrics 88 (1991) 527-532
10. Yuksel B., and Greenough A. Birthweight and hospital readmission in infants born prematurely. Arch Pediatr Adolesc Med. 148 (1994) 384-388
11. American Academy of Pediatrics: Committee on Infectious Disease and Committee on fetus and Newborn Prevention of respiratory Syncytial Virus Infection. Indication for the use of palivizumab and follow-up data on the use of RSV-IG. Pediatrics 1998; 102: 1211-1216.
12. Feltes T.F., Cabalka A.K., Meissner H.C., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 143 (2003) 532-540
13. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of Palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatr 2004; 112: 1442-1446.
14. Reeve C.A., Whitehall J.S., Buettner P.G., et al. Predicting respiratory syncytial virus hospitalization in Australian children. J Paediatr Child Health. 42 (2006) 248-252
15. Grimaldi M., Gouyon B., Sagot P., et al. Burgundy Perinatal Network. Palivizumab efficacy in preterm infants with gestational age < or equal 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol. 42 (2007) 189-192
16. Navas L., Wang E., deCarvalho V., et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalised population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 121 (1992) 348-354
17. Purcell K., and Fergie J. Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991to 2002. Pediatr Infect Dis J. 23 (2004) 418-423
18. Thompson W.W., Shay D.K., Weintraub E., et al. Mortality associated with influenza and respiratory virus in the United States. JAMA. 289 (2003) 170-186
19. Fleming D.M., Pannell R.S., and Cross K.W. Mortality from influenza and respiratory syncytial virus. J Epidemiol Community Health. 59 (2005) 589-590
20. Infectious Diseases and Immunization Committee, Canadian Paediatric Society, Respiratory syncytial virus immune globulin intravenous. Pediatr Child Health 1998; 3: 11-14.
21. Posfay-Barbe K.M., Zerr D.M., and Pittet D. Infection control in paediatrics. Lancet. 8 (2008) 19-30
22. Simoes E.A., Sondheimer H.M., Top Jr. F.H., et al., The Cardiac Study Group. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus in infants and children with congenital heart disease. J Pediatr. 133 (1998) 492-499
23. Groothius J.R., Simoes E.A., and Levin M.J. Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Eng J Med. 329 (1993) 1524-1530
24. Simoes E.A., and Groothius J.R. Respiratory syncytial virus prophylaxis-the story so far. Respir Med 96 Suppl B (2002) S15-S24 Review
25. Carbonell-Estrany X., Giuffre L., Kimpen J.L.L., et al. Guidelines for the use of Synagis [palivizumab], a humanized monoclonal antibody, for the prevention of respiratory syncytial virus [RSV] disease in high-risk infants: A consensus opinion. Infect Med. 16 (1999) 29-33
26. Meissner H.C., Groothius J.R., Rodriguez W.J., et al. Safety and pharmacokinetics of an intramuscular monoclonal antibody [SB 209763] against respiratory syncytial virus [RSV] in infants and young children at risk for severe RSV disease. Antimicrob Agents Chemother. 43 (1999) 1183-1188
27. IMpact-RSV Study Group. Palivizumab, a humanized respiratory virus monoclonal antibody, reduced hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102: 531-537.
28. Johnson S., Oliver C., Prince G.A., et al. Development of a humanized monoclonal antibody [MEDI-493] with potent in vitro and in vivo activity against Respiratory Syncytial Virus. J Infect Dis. 176 (1997) 1215-1224
29. Subramanian K.N., Weisman L.E., Rhodes T., et al. Safety, tolerance and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 17 (1998) 110-115
30. Saez-Lorens X., Castano E., Null D., et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J. 17 (1998) 787-791
31. Fenton C., Scott L.J., Plosker G.L., and Palivizumab:. A Review of its Use as Prophylaxis for Serious Respiratory Syncytial Virus Infection. Pediatr Drugs. 6 (2004) 177-197
32. Lanari M., Rossi G.A., Merolla R., et al. High risk of nosocomial-acquired RSV infection in children with congenital heart disease. J Pediatr. 145 (2004) 140
33. Sigurs N., Bjarnason R., Sigurbergsson F., et al. Respiratory Syncytial Virus Bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 161 (2000) 1501-1507
34. Sigurs N, Gustafsson P, Bjarnason R et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171: 137-141.
35. Pullan C.R., and Hey E.N. Wheezing, asthma and pulmonary dysfunction 10 years after infection with respiratory syncytial virus. BMJ. 284 (1982) 1665-1669
36. Stein R.T., Sherril D., Morgan W.J., et al. Respiratory Syncytial Virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 354 (1999) 541-545
37. Korppi M., Piippo-Savolainen E., Korhonen K., et al. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 38 (2004) 155-160
38. Robertson C.F., Roberts M.F., and Kappers J.H. Asthma prevalence in Melbourne schoolchildren: have we reached the peak?. Med J Aust. 180 (2004) 273-276
39. Naver L., Eriksson M., Ewald U., et al. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden. Acta Paediatr. 93 (2004) 1470-1473
40. Tulloh R.M., and Feltes T.F. The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital heart disease. Cardiol Young. 15 (2005) 274-278 Review
41. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health. 36 (2000) 422-427
42. Vogel A.M., Lennon D.R., Broadbent R., et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high risk infants. J Paediatr Child Health. 38 (2002) 550-554
43. Nuijten M.J., Wittenberg W., and Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high risk children: A UK analysis. Pharmacoeconomics. 25 (2007) 55-71
44. Meberg A., and Bruu A.L. Respiratory syncytial virus infections in congenital heart defects-hospitalizations and costs. Acta Paediatr. 95 (2006) 404-406
45. http://www.copdx.org.au/guidelines/a_ref_1.asp#ref5.